# SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease

> **NCT00725478** · — · COMPLETED · sponsor: **Desitin Arzneimittel GmbH** · enrollment: 250 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Piribedil

## Key facts

- **NCT ID:** NCT00725478
- **Lead sponsor:** Desitin Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2010-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725478, "SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00725478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*